Dr Li talks to ecancer at ASCO 2017 about results from a phase II basket trial looking at Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers.

Human epidermal growth factor receptor 2 (HER2, ERBB2) mutations occur in 2% of lung cancers, resulting in receptor dimerisation and kinase activation with in vitro sensitivity to trastuzumab. Ado-trastuzumab emtansine is a HER2 targeted antibody drug conjugate linking trastuzumab with the anti-microtubule agent emtansine.

Ado-trastuzumab emtansine is active and well tolerated in pts with HER2 mutant lung cancers.

свернуть